CONMED Corporation
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CNMD research report →
Range $36 – $50
Price Chart
About the company
CONMED Corporation functions as a medical technology enterprise, specializing in the global development, production, and distribution of surgical instruments and related apparatus for a variety of surgical procedures. Its comprehensive product portfolio includes specialized orthopedic surgical items, such as the TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-Knot All-Suture Anchors, and PopLok Knotless Suture Anchors. These innovative offerings provide unique clinical advantages to orthopedic surgeons for repairing soft tissue injuries and are complemented by supportive tools that facilitate minimally invasive sports medicine operations.
- CEO
- Patrick J. Beyer
- IPO
- 1987
- Employees
- 3,900
- HQ
- Largo, FL, US
Get TickerSpark's AI analysis on CNMD
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.39B
- P/E
- 19.84
- Fwd P/E
- 10.18
- PEG
- 1.14
- P/S
- 1.04
- P/B
- 1.36
- EV/EBITDA
- 10.40
- Div Yield
- 0.00%
- Gross Margin
- 57.20%
- Op Margin
- 12.11%
- Net Margin
- 5.36%
- ROE
- 7.07%
- ROIC
- 5.73%
Latest fiscal year · YoY change
- Revenue
- $1.37B+5.2%
- Gross Profit
- $725.38M-1.0%
- Op Income
- $141.13M
- Net Income
- $47.05M-64.5%
- EPS
- $1.52-64.6%
- OCF Growth
- +2.2%
- FCF Growth
- -2.0%
- 52W High
- $54.80
- 52W Low
- $31.44
- 50D MA
- $47.23
- 200D MA
- $42.08
- Beta
- 0.90
- RSI (14)
- 43
- Avg Volume
- 362.16K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
ConMed delivered a solid third quarter, with organic constant-currency growth and EPS ahead of expectations, and raised/trimmed full-year guidance to reflect stronger FX, GI exits, and a more measured Q4 outlook.· October 28, 2026
- Q3 revenue was $335.6 million; net sales were down 70 bps reported and 80 bps constant currency, but organic constant-currency revenue grew 6.7%.
- Adjusted diluted EPS was $1.04, above the high end of expectations; adjusted gross margin was 56.4% and adjusted operating margin was 15.4%.
- General surgery organic constant-currency sales rose 6.4% and orthopedic surgery rose 7.2%, driven by AirSeal, Buffalo Filter direct smoke evacuation, and BioBrace.
- Management raised full-year 2026 EPS guidance and reaffirmed at least 5% organic constant-currency growth, while narrowing the top end of the sales range after assuming less Q4 sequential improvement.
- Cash generation remained solid, with $46.4 million of free cash flow in Q3 and leverage at 2.7x after refinancing activity.
Third-quarter net revenue was $335.6 million. Net sales decreased 70 basis points as reported and 80 basis points on a constant-currency basis, while organic constant-currency net revenue increased 6.7% year over year. Adjusted diluted EPS was $1.04 versus $1.08 last year; adjusted net income was $31.4 million versus $33.4 million. Adjusted gross margin was 56.4%, up 40 basis points, and adjusted operating margin was 15.4%, up 20 basis points. Free cash flow was $46.4 million, down 3.6% year over year. For 2026, management now expects organic constant-currency net sales growth of 5% to 5.5% (from 5% to 6%), adjusted EPS of $4.54 to $4.61 (from $4.48 to $4.60), adjusted gross margin of about 57.5%, free cash flow of about $115 million, and Q4 adjusted EPS of $1.23 to $1.30. The company also said Q4 GAAP net sales are expected to be $364 million to $370 million, excluding about $3.7 million of GI revenue and a roughly $650 thousand FX tailwind.
Patrick Beyer said Q3 reflected solid execution and a more focused portfolio after exiting GI products, with the company concentrating on minimally invasive surgery, smoke evacuation, and orthopedic soft tissue repair. He highlighted AirSeal, direct Buffalo Filter smoke evacuation, and BioBrace as the core growth engines, and said the company is gaining share across new regions and clinical settings. His tone was confident and constructive, emphasizing long-term growth opportunities, underpenetration in key markets, and continued traction from clinical evidence and expanded regulatory/labeling reach.
John Gallagher said adjusted gross margin was 56.4%, helped by favorable product mix, while adjusted operating expenses were essentially flat and adjusted interest expense rose to $10.5 million from $6.3 million due to refinancing. He noted the company drew on a new $450 million term loan and revolver to repurchase $645.2 million of convertible notes, leaving cash at $48 million, total debt at $815.9 million, available borrowing capacity at $468.5 million, and leverage at 2.7x. He also pointed to $49.9 million of share repurchases in the first nine months and a full-year target of $62 million, plus updated 2026 guidance that includes about $33.7 million of adjusted interest expense and an adjusted tax rate of about 24.5%.
Analysts focused on why the full-year sales midpoint was reduced more than the Q3 shortfall, and management said the main drivers were stronger FX and a lower GI revenue assumption, while also backing off an assumed Q4 rebound because Q3 international timing benefited results and should not repeat. Questions also centered on softness in U.S. general surgery and orthopedics; management attributed that mostly to OEM Buffalo Filter volatility and the ongoing commercial reorganization in orthopedics, saying the U.S. ortho trends are improving and the business should return to growth next year. On capital allocation and strategy, management said it is focused near term on cash generation, lower leverage, buybacks, and evaluating revenue-growth-accretive M&A, but declined to comment on rumors or provide a 2027 outlook.
The company posted 6.7% organic constant-currency growth and beat EPS expectations while keeping margins relatively healthy, suggesting the core businesses are still growing despite portfolio exits and restructuring. Management sounded confident that AirSeal, Buffalo Filter direct, and BioBrace each have meaningful long-term runway, supported by clinical data, regulatory wins, and legislative tailwinds for smoke evacuation.
The revised sales guide reflects less confidence in a strong Q4 acceleration, and management acknowledged that some Q3 international strength was timing-related rather than fully repeatable. There are also ongoing headwinds from OEM Buffalo Filter volatility, a still-recovering U.S. orthopedic business, higher interest expense after refinancing, and a gross margin base that was helped by mix but also affected by discrete operational and inventory items.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 99.6%
- Shares Outstanding
- 29.80M
- Float Shares
- 29.69M
of shares held by institutions
251 13F filers
Buy/sell ratio 0.50. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for CNMD, newest first.
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Blackrock, Inc. | 4.94M | ▲ 114.59K |
| Vanguard Group Inc | 3.68M | ▲ 73.53K |
| Earnest Partners LLC | 2.48M | ▼ 26.98K |
| Vanguard Portfolio Management LLC | 2.21M | ▲ 22.33K |
| Fuller & Thaler Asset Management, Inc. | 1.48M | ▼ 99.76K |
| Dimensional Fund Advisors LP | 1.47M | ▲ 156.59K |
| State Street Corp | 1.40M | ▼ 20.25K |
| Bank Of America Corp | 1.34M | ▼ 4.27K |
| Vanguard Capital Management LLC | 1.33M | ▼ 28.21K |
| Sei Investments Co | 950.08K | ▼ 38.07K |
| Capital Research Global Investors | 822.24K | ▼ 1.39K |
| Geode Capital Management, LLC | 713.17K | ▼ 76.97K |
Held by 348 ETFs
Biggest fund positions in CNMD by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Nov 4, 26 | Foust Hollie K | other | 4,000 |
| Nov 4, 26 | Foust Hollie K | other | 1,124 |
| Nov 4, 26 | Foust Hollie K | other | 4,000 |
| Sep 8, 26 | Kelderman Kim | other | 500 |
| Sep 8, 26 | Kelderman Kim | other | 500 |
| Jul 15, 26 | Gallagher John E | other | 26,875 |
| Jul 15, 26 | Gallagher John E | other | 35,054 |
| Jul 15, 26 | Gallagher John E | other | 30,536 |
| Jul 15, 26 | Gallagher John E | other | 0 |
| Jul 1, 26 | Martin Celine Christine | other | 5,603 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our CNMD coverage
Recent articles, reports, and earnings notes.
No research on CNMD yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CNMD report →Here's Why You Should Retain CONMED Stock in Your Portfolio for Now
zacks.com · Nov 12
CONMED Corporation to Participate in the Jefferies Global Healthcare Conference
businesswire.com · Nov 2
CONMED Q3 Earnings Call Highlights
marketbeat.com · Oct 29
CONMED Corporation (CNMD) Q3 2026 Earnings Call Transcript
seekingalpha.com · Oct 29
Conmed (CNMD) Q3 Earnings Top Estimates
zacks.com · Oct 28
Here's What Key Metrics Tell Us About Conmed (CNMD) Q3 Earnings
zacks.com · Oct 28
CONMED Corporation Reports Third Quarter 2026 Financial Results; Updates Full Year 2026 Guidance
businesswire.com · Oct 28
Is Conmed Corp (CNMD) a Bargain After 6.0% Drop? GF Value Says Undervalued
gurufocus.com · Oct 6
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.